Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction.
Growing evidence suggests that proinflammatory responses will be a crucial issue for developing neuropsychiatric disorders. Recent clinical trials demonstrated that adjunctive therapy of cyclo-oxygenase (COX)-2 inhibitor was effective for major depression. Here, we present the case of an elderly depressed woman with acute cognitive deficit who was refractory to multiple antidepressants but only responsive to celecoxib, a COX-2 inhibitor, in acute treatment and sustaining remission for a 5-year treatment course. Our finding suggests that a therapeutic effect of celecoxib exists for major depressive disorder comorbid with neurocognitive dysfunction.
Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
Chun-Yen
CY
Chen
Nian-Sheng
NS
Tzeng
Yi-Chyan
YC
Chen
D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D000068579:Celecoxib; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D015897:Comorbidity; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008609:Mental Status Schedule; D010343:Patient Admission; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
D000928:Antidepressive Agents; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib